Chapter 3: The Supply She Could Stop

HelixNorth's manufacturing team ran three scenarios before the court hearing. Full shutdown protected the patent but stranded patients. Unrestricted continuation protected treatment while allowing Mercer to claim implied consent. The direct emergency license preserved clinical use and separated it from financing.

Nora attached forecasts for cartridge production, staffing, transport, and adverse-event monitoring. The plan cost HelixNorth nearly two million dollars. The board created a reserve funded from unrestricted cash and sought reimbursement later through litigation.

No executive bonus could be paid while patient continuity drew from the reserve. Nora waived her salary first, but Amara prevented her from waiving health coverage or legal defense. Personal sacrifice made good headlines and bad governance if it weakened the person responsible for trial safety.

The company also invited competing logistics providers to bid for future sites. Mercer properties could participate on equal terms after curing conflicts. Revocation removed privilege, not eligibility forever.

Grant treated revocation as bluff.

Mercer Crown continued advertising proprietary access and ordered its pharmacy partner to draw another month of trial cartridges. HelixNorth's fulfillment system rejected the request.

Grant sought an emergency order forcing supply, claiming Nora used patent ownership to harm patients during divorce.

At court, Nora produced the emergency license issued directly to care providers, current inventory, and transfer protocols. No patient needed to miss treatment. Mercer had to allow hospital teams access without marking cartridges as hotel assets.

Grant's lawyer argued the distinction was artificial.

“It is the distinction between hosting medicine and owning it,” Nora said.

The judge denied compelled commercial supply but ordered daily continuity reports. HelixNorth could protect ownership only while maintaining reasonable patient access.

Nora accepted the obligation.

Grant attempted to block hospital staff from Mercer sites unless HelixNorth reinstated his license. Patients and families protested in the lobby. Nora negotiated temporary access agreements with each property manager, paying room costs at ordinary rates while reserving damages.

One patient, twelve-year-old Liam Price, could not transfer safely because his infusion protocol depended on calibrated equipment built into the Mercer suite. His mother confronted Nora outside court.

“Corporate distinctions do not matter if the machine stops.”

“You are right,” Nora said.

She entered a limited site license for Liam and nine others whose care could not move. It granted no financing rights and expired after clinical transfer.

The decision weakened her leverage but protected people who never consented to become it.

Amara then discovered cartridge inventory was lower than Mercer reported. Twenty patient doses had been diverted into a private trial not registered with HelixNorth.

Stopping unauthorized supply had exposed a continuity crisis already underway.

The unauthorized private trial involved wealthy guests receiving experimental preservation cartridges outside approved protocols. Some paid Mercer concierge fees. Others believed enrollment was legitimate because the hotel displayed HelixNorth branding.

Nora suspended those uses immediately and notified regulators. She offered medical evaluation without requiring patients to waive claims or identify publicly. Grant accused her of abandoning them after Mercer collected payment.

“You enrolled them,” she said. “HelixNorth will manage safety. Mercer will account for the money.”

Daily continuity reports tracked dose, location, device calibration, transfer readiness, and responsible clinician. Personal identifiers stayed with hospitals. The court received aggregate status unless a patient consented to details.

Liam's case exposed why a simple shutdown was impossible. His infusion schedule could not tolerate equipment movement for ten days. Nora negotiated access through the property's general manager, not Grant. Hotel staff provided utilities and room services; clinical staff controlled equipment and drug inventory.

Liam's mother asked whether Nora would promise the therapy worked. Nora refused certainty. The trial showed encouraging response but carried known risks and unknown long-term outcomes. Honest limits did not comfort as quickly as promises. They allowed informed choice.

Other families formed a patient council. They wanted notice before licensing changes, a voice in transfer plans, and protection from being used in corporate statements. HelixNorth agreed and funded independent advisers.

Grant attempted to stage a press event with two grateful patients. The council declined. One family participated anyway, describing Mercer staff kindly while criticizing management. Nora protected their right to speak even when the message complicated her case.

The court's continuity order also constrained HelixNorth. Nora could not revoke access on short notice while patients remained dependent. In return, Mercer could not block clinicians or claim the emergency license as an asset. Both sides posted bonds for violations.

Amara reconciled cartridge serial numbers and found twenty missing units shipped to an unregistered suite controlled by Mercer philanthropy. Vivian chaired that foundation.

Security logs showed late-night deliveries approved by the compliance chief. Trial data from those units never reached HelixNorth, creating unknown safety exposure.

Nora expanded recalls carefully. Units with verified patient use remained under clinician supervision. Unassigned stock had to return sealed. The distinction prevented panic and protected evidence.

Grant finally understood the supply was stopped, but he still believed Nora would restore it if he threatened enough consequence. He filed guardianship the next morning.

The patient council selected two representatives for continuity meetings and one medical ethicist paid by HelixNorth but chosen independently. Their first demand was a prohibition on sudden site changes for litigation advantage. Nora agreed and added minimum notice except immediate safety risk.

One representative challenged the company's free emergency license. If free access ended after sixty days, hospitals might face price shock. HelixNorth published transitional pricing capped at manufacturing cost plus a modest service margin until trials concluded.

Grant's hotel managers complained they carried utility and staffing expenses. Nora negotiated reasonable facility payments directly, separating legitimate hosting costs from patent ownership. Properties that cooperated received prompt payment; claims against corporate management remained reserved.

The diverted cartridges raised possible dosing errors because private-trial patients lacked calibrated monitoring. HelixNorth opened a confidential hotline and offered testing. Seven people came forward. Two required intervention but recovered.

Vivian denied authorizing the private trial despite chairing the foundation. Her electronic approval appeared on shipments, making authentication the next dispute. The same compliance chief who notarized Nora's forged consent controlled Vivian's credential system.